Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Enochian BioSciences Inc. (“Enochian” or the “Company”) (Nasdaq: ENOB), a company that purports to be a biotechnology company.
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Enochian BioSciences Inc. (“Enochian” or the “Company”) (Nasdaq: ENOB), a company that purports to be a biotechnology company.
On May 26, 2022, the Wall Street Journal published a story titled “Biotech Founder Arrested in Murder-for-Hire Scheme” in which it reported that “[t]he co-founder of Enochian BioSciences Inc. was arrested this week after being indicted on charges he was involved in a murder-for-hire scheme that led to the death of a Vermont man in 2018.” The article further reported that “Serhat Gumrukcu, 39 years old, was arrested on Tuesday after being charged by a grand jury with conspiring to commission a murder that resulted in the death of Gregory Davis, who was found dead in a snowbank several miles from his Vermont residence, the U.S. attorney for Vermont said on Wednesday.”
Following this news, shares of Enochian declined from a closing price on May 24, 2022 of $5.87 per share, to close at $3.70 per share on May 25, 2022, a decline of $2.17 per share, or over 36%, on heavier than usual volume.
If you own, purchased or otherwise acquired shares in Enochian securities and would like to discuss our investigation, please contact us by emailing jcampisi@kaplanfox.com or by calling (212) 687-1980.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Kaplan Fox & Kilsheimer LLP, with offices in New York, Oakland, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this investigation, your rights, or your interests, please contact:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(212) 687-1980
E-mail: jcampisi@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com
